Curi RMB Capital LLC Buys 805 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Curi RMB Capital LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.9% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 87,850 shares of the biopharmaceutical company’s stock after buying an additional 805 shares during the period. Curi RMB Capital LLC’s holdings in Gilead Sciences were worth $7,365,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Manning & Napier Advisors LLC acquired a new stake in Gilead Sciences in the second quarter worth about $25,328,000. Legal & General Group Plc lifted its holdings in Gilead Sciences by 0.8% in the second quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after buying an additional 93,068 shares during the period. IRON Financial LLC bought a new position in Gilead Sciences in the third quarter valued at approximately $830,000. Wealth Enhancement Advisory Services LLC grew its holdings in Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after acquiring an additional 33,162 shares during the period. Finally, Cetera Investment Advisers raised its position in shares of Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company’s stock valued at $15,668,000 after acquiring an additional 119,909 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 0.6 %

Gilead Sciences stock opened at $92.11 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.82 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a fifty day simple moving average of $86.22 and a 200 day simple moving average of $75.69. The company has a market cap of $114.79 billion, a P/E ratio of 1,023.44, a price-to-earnings-growth ratio of 2.85 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the previous year, the business earned $2.29 earnings per share. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. Research analysts anticipate that Gilead Sciences, Inc. will post 4.39 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.34%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is presently 3,422.22%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,947 shares of company stock valued at $4,968,674. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on GILD. Robert W. Baird raised their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company upped their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, ten have issued a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $93.10.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.